The efficacy of SARS-CoV-2 vaccination in IBD has been explored in adult studies, showing an attenuated SARS-CoV-2 vaccine response for patients treated with anti-TNF alone or in combination with an immunomodulator (IM) compared with those treated with vedolizumab [10,11,12]. Here, TNF is linked to inflammatory bowel disease.